Maria-Victoria Mateos of Salamanca University in Spain on melphalan as the better partner drug for bortezomib in multiple myeloma; Commentary Dr. Canellos and Jesus San-Miguel, also of Salamanca, and Richard Van Etten of Tufts University.

Steven Devine of Ohio State University on T-cell depletion to avoid GVHD in AML; commentary from Dr. Canellos and Armand Keating of the University of Toronto.

Download (3.91 MB)

+ Favorites

Program 3, Monday Dec 7

Creator: Peter Goodwin
Duration: 23:20

Oncology Times

George Canellos on aggressive chemotherapy's failure to benefit patients with high-risk B-cell lymphoma.

Massimo Martelli of University of Perugia on infused donor T-regulatory cells to prevent graft-vs-host-disease in patients with leukemia & lymphoma; comments from Armand Keating of the University of Toronto.

Mathias Rummel of University Hospital in Germany on using bendamustine rather than CHOP combined with rituximab for treating indolent lymphomas—front-line. Commenting: Dr. Canellos and Richard Van Etten of Tufts University.

Eduardo Rego of the University of Sao Paolo on his networking between North and South America to improve treatment of APL in developing countries. Adding their thoughts: Dr. Canellos and Richard Larson of the University of Chicago. OT Interviewers: Peter Goodwin and Sarah Maxwell.

Download (4.88 MB)

+ Favorites

Program 4, Day 4, Monday Dec 8

Creator: Peter Goodwin
Duration: 22:07

Oncology Times

Prof Giuseppe Saglio of the University of Turin and San Luigi Gonzaga Hospital in Italy on nilotinib as a new standard of care for chronic myeloid leukaemia. ASH President Nancy Berliner of Brigham & Women's Hospital adds her thoughts.

Jorge Cortes of M. D. Anderson Cancer Center on three different ASH papers by his group looking at alternatives to standard imatinib in CML. Jane Apperley of Hammersmith Hospital and Imperial College London, reflects on these, and discusses strategies for dealing with imatinib resistance.

OT Broadcast News Scientific Editor George Canellos of Dana-Farber Cancer Institute on what some were jokingly calling a re-run of World War II that took place in the Non-Hodgkin’s Lymphoma session: R-CHOP 14 vs R-CHOP 21 in elderly patients with diffuse large B-cell lymphoma.

Andrzej Jakubowiak of the University of Michigan discusses a 4-drug regimen to treat newly diagnosed multiple myeloma....Ruben Niesvizky of Weill Cornell Medical College in New York City on the novel proteasome inhibitor carfilzomib, used in combination with lenalidomide and dexamethasone to treat relapsed or refractory multiple myeloma. OT interviewers: Peter Goodwin and Sarah Maxwell.

Download (4.89 MB)

+ Favorites

From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)

Duration: 8:12

Oncology Times

Speaking at the meeting in Barcelona, Gilles Salles of the University of Lyon discusses the results showing that patients who had achieved remissions after immunochemotherapy had only half the risk of recurrence if they also received rituximab maintenance therapy for two years compared with patients who did not.

Download (1.93 MB)

+ Favorites

Collection Alerts

Stay up-to-date! Be notified every time a new item is added. Receive an Email or subscribe to an RSS feed.

Subscribe to Collection Alerts

Subscribe to the Topical Collection RSS Feed

Login

Register for a free account